HIV Infections
Conditions
Brief summary
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines. The study examined whether VRC01 controlled or delayed the return of HIV viremia when the participants' HIV medicines were briefly stopped during the study.
Detailed description
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of a human monoclonal antibody, VRC-HIVMAB060-00-AB (known as VRC01), in HIV-infected adults whose HIV was well-controlled with antiretroviral therapy (ART). The study examined whether VRC01 delayed or prevented the return of HIV viremia in participants who underwent a brief analytical treatment interruption (ATI). The study enrolled HIV-infected participants 18 years and older who were on ART (ART was not provided by the study). At a pre-entry study visit, participants underwent blood collection, a leukapheresis procedure, and a rectal biopsy. The study lasted about 34 weeks and proceeded in three stages: Step 1 (approximately 9 weeks), Step 2 (approximately 12 weeks), and Step 3 (approximately 13 weeks). During Step 1, participants received three doses of VRC01 via intravenous (IV) infusion. The first dose of VRC01 was given on day 0. Seven days after receiving this first dose of VRC01, participants discontinued ART. Participants received the second and third doses of VRC01 at days 21 and 42, respectively. For 7 days after each VRC01 IV infusion, participants monitored and recorded their temperature and any symptoms. In addition to the 3 infusion study visits, participants attended weekly visits from day 7 through approximately day 63 (week 9). Participants entered Step 2 of the study and resumed ART when they had a confirmed CD4+ T-cell count of less than 350 cells/μL or a confirmed return of HIV-1 viremia, defined per protocol as an HIV-1 RNA measurement of greater than or equal to 200 copies/mL followed by a confirmatory measurement of greater than or equal to 1000 copies/mL or three consecutive HIV-1 RNA measurements of over 200 copies/mL. Step 2 study visits occurred on the day ART was resumed (Step 2, entry) and every four weeks thereafter (approximately at Step 2, weeks 4, 8, and 12) until a participant's HIV viral load decreased to less than 50 copies/mL. Throughout the study, visits included clinical assessments and blood collection. Some blood was stored for future testing. Some study visits included the collection of oral, rectal, and (for women) cervical secretion samples. On day 63, participants underwent another leukapheresis procedure and a rectal biopsy. Participants who completed Step 2 may have optionally entered Step 3 for additional testing. Entry into Step 3 occurred at least 3 months after the participant had completed Step 2. Step 3 participants had additional study visits for a leukapheresis procedure, a rectal biopsy, and clinical follow up.
Interventions
BIOLOGICALVRC01
40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP. Administered over about 30 to 60 minutes using a volumetric pump.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Step 1 Inclusion Criteria: * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load (VL). More information on this criterion can be found in the protocol. * Ability and willingness of participant or legal representative to provide informed consent * Clinically stable on their first or second ART regimen that includes a boosted protease inhibitor or an integrase inhibitor. The current regimen should have been stable for 8 weeks at the time of entry. Changes while the patient HIV viral load was undetectable did not count toward the number of ART regimens used, (for example, an individual switching from a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to an integrase inhibitor based regimen while the HIV viral load is undetectable would still be on their first regimen). * HIV-1 RNA that is less than 50 copies/mL using a Food and Drug Administration (FDA)-approved assay performed by any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent within 45 days prior to study entry * HIV-1 RNA less than 50 copies/mL using a FDA-approved assay for at least 24 weeks prior to study entry performed by any laboratory that had a CLIA certification or its equivalent. More information on this criterion can be found in the protocol. * Screening CD4+ T-cell count greater than or equal to 450 cells/μL within 45 days prior to study entry * Nadir CD4+ T-cell count greater than 200 cells/μL * Willingness to have blood samples collected, stored indefinitely, and used for study-related research purposes * The following laboratory values obtained within 45 days prior to enrollment: * Absolute neutrophil count (ANC) greater than or equal to 1000 cells/mm\^3 * Hemoglobin greater than or equal to 12.0 g/dL for men and greater than or equal to 11.0 g/dL for women * Platelet count greater than or equal to 100,000/mm\^3 * Creatinine clearance greater than or equal to 60 mL/min estimated by the Cockcroft-Gault equation. More information on this criterion can be found in the protocol. * Alanine aminotransferase (ALT) less than or equal to 2.0 times the upper limit of normal (ULN) * At least eight participants had availability of plasma or serum specimen before the initiation of ART either in the Center for AIDS Research (CFAR) repository of the University of Pennsylvania, University of Alabama, or in the AIDS Clinical Trials Group (ACTG) central repository * For females of reproductive potential (i.e., women who have not been post-menopausal for at least 24 consecutive months; who had menses within the preceding 24 months; or women who had not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy), negative urine pregnancy test (with a sensitivity of 15 to 25 mIU/mL) within 48 hours prior to screening and entry. More information on this criterion can be found in the protocol. * Contraceptive methods were required for female participants of reproductive potential. Female participants of reproductive potential and their male partners MUST HAVE appropriately used at least two contraceptives, with one method being highly effective and the other method being either highly effective or less effective. More information on this criterion, including a list of acceptable contraceptive options, can be found in the protocol. * Contraceptive methods were required for female partners of reproductive potential of male study participants on study drug. Female partners of reproductive potential of male study participants and/or their male partners MUST HAVE appropriately used at least two contraceptives, with one method being highly effective and the other method being either highly effective or less effective. More information on this criterion, including a list of acceptable contraceptive options, can be found in the protocol. * Negative hepatitis B surface antigen (HBsAg) result obtained within 6 months prior to study entry * Hepatitis C virus (HCV) antibody negative result within 6 months prior to entry, or if the HCV antibody result was positive, a negative HCV RNA obtained within 6 months prior to study entry * Adequate venous access in at least one arm Step 2 Inclusion Criteria: * Entry into Step 1 of this study (A5340) * Receipt of at least one dose or partial dose of VRC01 in Step 1 * Reinitiating ART for protocol or non-protocol-defined reasons. More information on this criterion can be found in the protocol. Step 3 Inclusion Criteria: * Entry into and completion of Step 2 of this study (A5340) at least 3 months prior * HIV-1 RNA less than 50 copies/ml at pre-entry visit * Ability and willingness of participant or legal representative to provide informed consent * Willingness to have blood samples/specimens collected, stored indefinitely, and used for study-related research purposes * Adequate venous access in at least one arm Step 1
Exclusion criteria
* Previous receipt of humanized or human monoclonal antibody whether licensed or investigational * Weight greater than 115 kg or less than 53 kg * History of an AIDS-defining illness * Ongoing AIDS-related opportunistic infection (including oral thrush) * History of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis in the 2 years prior to enrollment * Currently breastfeeding * Receipt of other investigational study agent within 30 days prior to enrollment * Treatment with systemic glucocorticoids (e.g., prednisone or other glucocorticoid) or other immunomodulators (other than nonsteroidal anti-inflammatory drugs \[NSAIDs\]) within 30 days prior to enrollment * Any other chronic or clinically significant medical condition that in the opinion of investigator would have jeopardized the safety or rights of the participant, including, but not limited to diabetes mellitus type I, OR clinically significant forms of drug or alcohol abuse, severe asthma, autoimmune disease, uncontrolled hypertension, liver disease, psychiatric disorders, heart disease, or cancer * Treatment during acute infection (i.e., treatment within 6 months of acute infection) * Current use of a NNRTI Step 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Experienced a Grade 3 or Higher Systemic (i.e., Not a Local Reaction) Adverse Event (AE) That is Possibly, Probably, or Definitely Related to the Administration of the VRC01 Antibody | Measured from entry through week 21 (Steps 1 and 2) | The primary safety outcome examined the occurrence of a Grade 3 or higher systemic (i.e., not a local reaction) adverse event (AE) possibly, probably, or definitely related to the administration of the VRC01 antibody. The DAIDS AE Grading Table (V2.0) was used. |
| Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 8 of the Analytical Treatment Interruption (ATI) or Indication to Re-initiate ART Prior to Week 8 of the ATI | Measured at Weeks 1, 2, 3, 4, 5, 6, 7, and 8 of the ATI | The primary efficacy outcome is the percentage of participants who had a confirmed HIV-1 RNA greater than or equal to 200 copies/mL at week 8 of the analytical treatment interruption (ATI) or indication to re-initiate ART prior to week 8 of the ATI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measured Value of Plasma VRC01 at the Time of Rebound | Measured from entry through week 21 (Steps 1 and 2) | Measured value of plasma VRC01, measured in micrograms per milliliter, at the time of rebound. Rebound is defined as the point in time when plasma HIV-1 RNA surpassed 40 copies/mL. |
| Measured Values of VRC01 in Plasma in the First 8 Weeks of the Analytical Treatment Interruption (ATI) | Measured at weeks 1, 2, 3, 4, 5, 6, 7, and 8 of the ATI | Measured values of plasma VRC01, measured in micrograms per milliliter, through week 8 of the ATI. The median and range of all VRC01 measurements taken in the first 8 weeks of the ATI were reported. |
| Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 4 of the ATI or Indication to Reinitiate ART Prior to Week 4 of the ATI | Measured at weeks 1, 2, 3, and 4 of the ATI | The secondary efficacy outcome was the percentage of participants who had a confirmed HIV-1 RNA greater than or equal to 200 copies/mL at week 4 of the ATI or indication to reinitiate ART prior to week 4 of the ATI. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| VRC01 Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
VRC01: 40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.
Administered over about 30 to 60 minutes using a volumetric pump. | 14 |
| Total | 14 |
Baseline characteristics
| Characteristic | VRC01 |
|---|---|
| Age, Continuous | 38 years |
| Age, Customized 18-29 years | 1 Participants |
| Age, Customized 30-39 years | 6 Participants |
| Age, Customized 40-49 years | 6 Participants |
| Age, Customized 50+ years | 1 Participants |
| BMI | 28.3 kg/m^2 |
| CD4 Cell Count | 896 cells/mm^3 |
| HIV-1 RNA < 20 copies/mL | 10 Participants |
| HIV-1 RNA < 40 copies/mL | 2 Participants |
| HIV-1 RNA = 40 copies/mL | 1 Participants |
| HIV-1 RNA = 50600 copies/mL | 1 Participants |
| Intravenous Drug History Never | 13 Participants |
| Intravenous Drug History Previously | 1 Participants |
| Race/Ethnicity, Customized Black Non-Hispanic | 6 Participants |
| Race/Ethnicity, Customized Hispanic (Regardless of Race) | 2 Participants |
| Race/Ethnicity, Customized White Non-Hispanic | 6 Participants |
| Region of Enrollment United States | 14 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 14 Participants |
| Weight | 86 kilograms |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 14 |
| other Total, other adverse events | 7 / 14 |
| serious Total, serious adverse events | 0 / 14 |
Outcome results
Primary
Percentage of Participants Who Experienced a Grade 3 or Higher Systemic (i.e., Not a Local Reaction) Adverse Event (AE) That is Possibly, Probably, or Definitely Related to the Administration of the VRC01 Antibody
The primary safety outcome examined the occurrence of a Grade 3 or higher systemic (i.e., not a local reaction) adverse event (AE) possibly, probably, or definitely related to the administration of the VRC01 antibody. The DAIDS AE Grading Table (V2.0) was used.
Time frame: Measured from entry through week 21 (Steps 1 and 2)
Population: All participants exposed to study treatment (VRC01) were included.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| VRC01 | Percentage of Participants Who Experienced a Grade 3 or Higher Systemic (i.e., Not a Local Reaction) Adverse Event (AE) That is Possibly, Probably, or Definitely Related to the Administration of the VRC01 Antibody | 0 percentage of participants |
Primary
Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 8 of the Analytical Treatment Interruption (ATI) or Indication to Re-initiate ART Prior to Week 8 of the ATI
The primary efficacy outcome is the percentage of participants who had a confirmed HIV-1 RNA greater than or equal to 200 copies/mL at week 8 of the analytical treatment interruption (ATI) or indication to re-initiate ART prior to week 8 of the ATI.
Time frame: Measured at Weeks 1, 2, 3, 4, 5, 6, 7, and 8 of the ATI
Population: Per protocol, the analysis population was limited to participants who received all scheduled VRC01 infusions and underwent an ATI according to protocol.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| VRC01 | Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 8 of the Analytical Treatment Interruption (ATI) or Indication to Re-initiate ART Prior to Week 8 of the ATI | 92 percentage of participants |
Secondary
Measured Value of Plasma VRC01 at the Time of Rebound
Measured value of plasma VRC01, measured in micrograms per milliliter, at the time of rebound. Rebound is defined as the point in time when plasma HIV-1 RNA surpassed 40 copies/mL.
Time frame: Measured from entry through week 21 (Steps 1 and 2)
Population: Per protocol, the analysis population was limited to participants who received all scheduled VRC01 infusions and underwent an ATI according to protocol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| VRC01 | Measured Value of Plasma VRC01 at the Time of Rebound | 127 micrograms/mL |
Secondary
Measured Values of VRC01 in Plasma in the First 8 Weeks of the Analytical Treatment Interruption (ATI)
Measured values of plasma VRC01, measured in micrograms per milliliter, through week 8 of the ATI. The median and range of all VRC01 measurements taken in the first 8 weeks of the ATI were reported.
Time frame: Measured at weeks 1, 2, 3, 4, 5, 6, 7, and 8 of the ATI
Population: Per protocol, the analysis population was limited to participants who received all scheduled VRC01 infusions and underwent an ATI according to protocol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| VRC01 | Measured Values of VRC01 in Plasma in the First 8 Weeks of the Analytical Treatment Interruption (ATI) | 175 micrograms/mL |
Secondary
Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 4 of the ATI or Indication to Reinitiate ART Prior to Week 4 of the ATI
The secondary efficacy outcome was the percentage of participants who had a confirmed HIV-1 RNA greater than or equal to 200 copies/mL at week 4 of the ATI or indication to reinitiate ART prior to week 4 of the ATI.
Time frame: Measured at weeks 1, 2, 3, and 4 of the ATI
Population: Per protocol, the analysis population was limited to participants who received all scheduled VRC01 infusions and underwent an ATI according to protocol.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| VRC01 | Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL at Week 4 of the ATI or Indication to Reinitiate ART Prior to Week 4 of the ATI | 62 percentage of participants |